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ABSTRACT
Aims To estimate the association of smoking status with rates of (i) infection, (ii) hospitalization, (iii) disease severity and
(iv) mortality from SARS‐CoV‐2/COVID‐19 disease.Design Living rapid review of observational and experimental stud-
ies with random‐effects hierarchical Bayesian meta‐analyses. Published articles and pre‐prints were identified via
MEDLINE and medRxiv. Setting Community or hospital, no restrictions on location. Participants Adults who received
a SARS‐CoV‐2 test or a COVID‐19 diagnosis.Measurements Outcomes were SARS‐CoV‐2 infection, hospitalization, dis-
ease severity and mortality stratified by smoking status. Study quality was assessed (i.e. ‘good’, ‘fair’ and ‘poor’).
Findings Version 7 (searches up to 25 August 2020) included 233 studies with 32 ‘good’ and ‘fair’ quality studies in-
cluded in meta‐analyses. Fifty‐seven studies (24.5%) reported current, former and never smoking status. Recorded
smoking prevalence among people with COVID‐19was generally lower than national prevalence. Current compared with
never smokers were at reduced risk of SARS‐CoV‐2 infection [relative risk (RR) = 0.74, 95% credible interval (CrI) = 0.58–
0.93, τ = 0.41]. Data for former smokers were inconclusive (RR = 1.05, 95% CrI = 0.95–1.17, τ = 0.17), but favoured
there being no important association (21% probability of RR ≥ 1.1). Former compared with never smokers were at some-
what increased risk of hospitalization (RR = 1.20, CrI = 1.03–1.44, τ = 0.17), greater disease severity (RR = 1.52,
CrI = 1.13–2.07, τ = 0.29) and mortality (RR = 1.39, 95% CrI = 1.09–1.87, τ = 0.27). Data for current smokers were
inconclusive (RR = 1.06, CrI = 0.82–1.35, τ = 0.27; RR = 1.25, CrI = 0.85–1.93, τ = 0.34; RR = 1.22, 95%
CrI = 0.78–1.94, τ = 0.49, respectively), but favoured there being no important associations with hospitalization andmor-
tality (35% and 70% probability of RR ≥ 1.1, respectively) and a small but important association with disease severity
(79% probability of RR ≥ 1.1). Conclusions Compared with never smokers, current smokers appear to be at reduced risk
of SARS‐CoV‐2 infection, while former smokers appear to be at increased risk of hospitalization, increased disease severity
and mortality from COVID‐19. However, it is uncertain whether these associations are causal.
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INTRODUCTION
COVID‐19 is a respiratory disease caused by the SARS‐
CoV‐2 virus. Large age and gender differences in case
severity and mortality have been observed in the ongoing
COVID‐19 pandemic [1]; however, these differences are
currently unexplained. SARS‐CoV‐2 enters epithelial cells
through the angiotensin‐converting enzyme 2 (ACE‐2)
receptor [2]. Some evidence suggests that gene expression
and subsequent receptor levels are elevated in the airway
and oral epithelium of current smokers [3,4], thus putting
smokers at higher risk of contracting SARS‐CoV‐2. Other
studies, however, suggest that nicotine down‐regulates
the ACE‐2 receptor [5]. These uncertainties
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notwithstanding, both former and current smoking is
known to increase the risk of respiratory viral [6,7] and
bacterial [8,9] infections and is associated with worse
outcomes once infected. Cigarette smoke reduces the respi-
ratory immune defence through peri‐bronchiolar inflam-
mation and fibrosis, impaired mucociliary clearance and
disruption of the respiratory epithelium [10]. There is also
reason to believe that behavioural factors (e.g. regular
hand‐to‐mouth movements) involved in smoking may
increase SARS‐CoV‐2 infection and transmission in
current smokers. However, early data from the COVID‐19
pandemic have not provided clear evidence for a negative
impact of current or former smoking on SARS‐CoV‐2 infec-
tion or COVID‐19 disease outcomes, such as hospitalization
or mortality [11]. It has also been hypothesized that
nicotine might protect against a hyperinflammatory
response to SARS‐CoV‐2 infection, which may lead to
adverse outcomes in patients with COVID‐19 disease [12].
There are several reviews that fall within the scope of
smoking and COVID‐19 [11,13–18]. We aimed to produce
a rapid synthesis of available evidence pertaining to the
rates of infection, hospitalization, disease severity and mor-
tality from SARS‐CoV‐2/COVID‐19 stratified by smoking
status. Given the increasing availability of data on this
topic, this is a living review with regular updates. As evi-
dence accumulates, the review will be expanded to include
studies reporting COVID‐19 outcomes by alternative nico-
tine use (e.g. nicotine replacement therapy or e‐cigarettes).
METHODS
Study design
This is a living evidence review, which is updated as new
evidence becomes available [19]. We adopted recom-
mended best practice for rapid evidence reviews, which
involved limiting the search to main databases and having
one reviewer extract the data and another verify [20]. This
study was not pre‐registered, but evolved from a report
written for a UK medical society [21]. The most recent
(and all future) version(s) of this living review is https://
www.qeios.com/read/latest‐UJR2AW. A completed Pre-
ferred Reporting Items for Systematic Reviews and
Meta‐Analyses (PRISMA) checklist is included in
Supporting information, Fig. S1.
Eligibility criteria
Studies were included if they:
1. Were primary research studies using experimental (e.
g. randomized controlled trial), quasi‐experimental (e.
g. pre‐ and post‐test;) or observational (e.g. case–con-
trol, retrospective cohort, prospective cohort) study
designs;
2. Included adults aged 16 + years;
3. Recorded as outcome (i) results of a SARS‐CoV‐2 diag-
nostic test (including antibody assays), (ii) clinical diag-
nosis of COVID‐19, (iii) hospitalization with COVID‐19,
(iv) severity of COVID‐19 disease in those hospitalized
or (v) mortality from COVID‐19;
4. Reported any of the outcomes of interest by self‐reported
or biochemically verified smoking status (e.g. current
smoker, former smoker, never smoker) or current
vaping or nicotine replacement therapy (NRT) use;
5. Were available in English; and
6. Were published in a peer‐reviewed journal, as a
pre‐print or a public health report by reputable agents
(e.g. governments, scientific societies).
Search strategy
The following terms were searched for in Ovid MEDLINE
(2019‐search date) as free text or Medical Subject
Headings:
1. Tobacco Smoking/ or Smoking Cessation/ orWater Pipe
Smoking/ or Smoking/ or Smoking Pipes/ or Cigar
Smoking/ or Smoking Prevention/or Cigarette
Smoking/ or smoking.mp. or Pipe Smoking/or Smoking,
Non‐Tobacco Products/or Smoking Water Pipes/
2. Nicotine/or nicotine.mp. or Electronic Nicotine Delivery
Systems/ or Nicotine Chewing Gum/
3. vaping.mp. or Vaping/
4. 1 or 2 or 3
5. Coronavirus/ or Severe Acute Respiratory Syndrome/or
Coronavirus Infections/ or covid.mp.
6. 4 and 5
The following terms were searched for in titles, abstracts
and full texts in medRxiv no time limitations):
1. covid (this term captures both covid and SARS‐CoV‐2)
AND smoking
2. covid AND nicotine
3. covid AND vaping
Additional articles/reports of interest were identified
through mailing lists, Twitter, the International Severe
Acute Respiratory and Emerging Infection Consortium
(ISARIC) and the US Centers for Disease Control and Pre-
vention (CDC). Where updated versions of pre‐prints or
public health reports were available, old versions were
superseded.
Selection of studies
One reviewer screened titles, abstracts and full texts against
the inclusion criteria.
Data extraction
Data were extracted by one reviewer and verified (i.e. inde-
pendently checked against pre‐prints and published re-
ports) by another on (i) author (year); (ii) date published;
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(iii) country; (iv) study design; (v) study setting; (vi) sample
size; (vii) sex; (viii) age; (ix) smoking status (e.g. current,
former, never, not stated, missing); (x) use of alternative
nicotine products; (xi) SARS‐CoV‐2 testing; (xii) SARS‐
CoV‐2 infection; (xiii) diagnosis of COVID‐19; (xiv) hospi-
talization with COVID‐19; (xv) disease severity in those
hospitalized with COVID‐19; and (xvi) mortality.
Quality appraisal
The quality of included studies was assessed to determine
suitability for inclusion in meta‐analyses. Studies were
judged as ‘good’ quality if they: (i) had< 20%missing data
on smoking status and used a reliable self‐report measure
that distinguished between current, former and never
smoking status; AND (ii) used biochemical verification of
smoking status and reported results from adjusted analy-
ses; OR reported data from a representative/random sam-
ple. Studies were rated as ‘fair’ if they fulfilled only
criterion (i) and were otherwise rated as ‘poor’. The quality
appraisal was conducted by one reviewer and verified by a
second.
Evidence synthesis
A narrative synthesis was conducted. Data from ‘good’ and
‘fair’ quality studies were pooled in Rversion 3.6.3 [22]. In
a living review where new data are regularly added to the
analyses, it may be more appropriate to use a Bayesian (as
opposed to frequentist) approach where prior knowledge is
used in combination with new data to estimate a posterior
risk distribution. A Bayesian approach mitigates against
the issue of performing multiple statistical tests, which
can inflate family‐wise error. A series of random‐effects
hierarchical Bayesian meta‐analyses were performed with
the brms [23] package to estimate the relative risk for each
comparison with accompanying 95% credible intervals
(CrIs). We first defined prior distributions for the true
pooled effect size (μ) and the between‐study heterogeneity
(τ), with μ specified as a normal distribution with a mean
equal to the derived point estimate from each comparison
of interest in the immediately preceding version of this liv-
ing review [24], and τ specified as a half‐Cauchy distribu-
tion with a mean of 0 and standard deviation of 1. The
half‐Cauchy distribution was selected to reflect prior
knowledge that high levels of between‐study heterogeneity
are more likely than lower levels. Markov chain Monte
Carlo methods (20000 burn‐ins followed by 80000 itera-
tions) were then used to generate a risk distribution for
each study, in addition to a pooled effect for the posterior
risk distribution. We report forest plots with the pooled
effect for the posterior risk distribution displayed as the
median relative risk (RR) with an accompanying 95% CrIs.
We used the empirical cumulative distribution function
(ECDF) to estimate the probability of there being a 10%
reduction or 10% increase in the RR (i.e. RR ≥ 1.1 or
RR ≤ 0.9). Due to a lack of indication as towhat constitutes
a clinically or epidemiologically meaningful effect (e.g. with
regard to onward disease transmission or requirements for
intensive care beds), we deemed a 10% change in risk as
small, but important. Where data were inconclusive (as
indicated by CrIs crossing RR = 1.0), to disambiguate
whether data favoured no effect or there being a small
but important association, we estimated whether there
was ≥ 75% probability of RR ≥ 1.1 or RR ≤ 0.9.
Two sensitivity analyses were performed. First, a
minimally informative prior for μwas specified as a normal
distribution with a mean of 0 and standard deviation of
1 and τ as described above. Second, an informative prior
as described above for μ was used with τ specified as a
half‐Cauchy distribution with a mean of 0.3 and
standard deviation of 1 to reflect greater between‐study
heterogeneity.
To aid in the visualization of smoking prevalence in the
included studies, 95% bootstrap percentile confidence
intervals (CIs) were calculated for each study. We
performed 1000 bootstrap replications, with the 2.5th
and 97.5th percentiles of the empirical distribution
forming the 95% bootstrap percentile CIs [25]. It should
be noted that prevalence estimates in the included studies
were not adjusted for age, sex, socio‐economic position or
region within countries.
DATA AVAILABILITY
All data contributing to the current and future review
versions are https://doi.org/10.6084/m9.
figshare.12756020. All code required to reproduce the
current and future analyses are https://doi.org/10.5281/
zenodo.4002046.
RESULTS
In the current review (version 7) with searches up to 25
August 2020, a total of 347 new records were identified,
with 233 studies included in a narrative synthesis and
32 studies included in meta‐analyses (see Fig. 1).
Study characteristics
Characteristics of included studies are presented in Table 1.
Studies were conducted across 33 countries. Sixty‐two
studies were conducted in the United States, 53 in China,
26 in the United Kingdom, 13 in Spain, 12 in Mexico, 11
in France, seven in Italy, six across multiple international
sites, four in Brazil and Iran, three in Israel and Turkey,
two in Bangladesh, Chile, Denmark, Finland, India, Japan
and Qatar and one from 15 further countries (see
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Supporting information, Fig. S1). The majority of studies
used observational designs (see Supporting information,
Table S1). One hundred and fifty‐five studies were con-
ducted in hospital settings, 62 studies included a commu-
nity component in addition to hospitalized patients, 14
studies were conducted exclusively in the community,
one study was conducted in a quarantine centre and one
did not state the study setting. Studies had a median of
404 (interquartile range = 115–1631) participants. The
majority of studies (93.5%) used reverse transcriptase–
polymerase chain reaction (RT–PCR) for confirmation of
SARS‐CoV‐2 infection, 2.6% used an antibody test to con-
firm prior infection and 3.9% further studies relied on a
combination of RT–PCR and clinical diagnosis (see
Supporting information, Table S1).
Smoking status
Categorization of smoking status was heterogeneous (see
Table 1). One hundred and forty‐five studies collected data
on smoking status through routine electronic health re-
cords (EHRs), 59 studies used a bespoke case report form
for COVID‐19 and 29 studies did not state the source for in-
formation on smoking status. None of the studies verified
smoking status biochemically. Notably, only 57 (24.4%)
studies reported current, former and never smoking status
(see Supporting information, Table S2a), with a further 17
studies reporting ever and never smoking status (see
Supporting information, Table S2b). The remaining 159
studies reported current, current/former or current and
former smoking status but did not explicitly state whether
remaining participants were never smokers or if data were
missing on smoking status (see Supporting information,
Table S2c). Seventy‐eight studies explicitly reported the
proportion with missing data on smoking status, which
ranged from 0.08 to 96.4%.
Use of alternative nicotine products
Five studies recorded the use of alternative nicotine prod-
ucts in current and/or former smokers but did not report
COVID‐19 outcomes stratified by nicotine use [26–30].
Quality appraisal
One study was performed in a random, representative pop-
ulation sample and was rated as ‘good’ quality. Forty‐six
studies were rated as ‘fair’ quality. The remaining 186
studies were rated as ‘poor’ quality (see Table 1).
Smoking prevalence by country
Unadjusted smoking prevalence compared with overall es-
timates for national adult smoking prevalence split by
country and study setting is presented in Fig. 2a,b. Lower
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow diagram of included studies.
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than expected current smoking prevalence was generally
observed. Former smoking prevalence was more similar
to expected prevalence when reported. National smoking
prevalence estimates used for comparison are presented
in Supporting information, Table S3.
SARS‐CoV‐2 testing by smoking status
Three studies provided data on access to SARS‐CoV‐2 diag-
nostic testing for those meeting local testing criteria by
smoking status. In a cohort study of US military veterans
aged 54–75 years [31], current smokers were more likely
to receive a test: 42.3% (1603 of 3789) of the sample were
current smokers comparedwith 23.8% of all veterans aged
50+ years using any tobacco product between 2010 and
2015 [32]. In the UK Biobank cohort [33], former
(RR = 1.29, 95% CI = 1.14–1.45, P< 0.001) and current
(RR = 1.44, 95% CI = 1.20–1.71, P < 0.001) compared
with never smokers were more likely to receive a test in a
multivariable analysis. In an Australian rapid assessment
screening clinic for COVID‐19 [34], 9.4% (397 of 4226)
of the self‐referred sample (subsequently assessed by a
health‐care professional to decide on testing) were current
smokers. Current compared with former or never smokers
were less likely to require a test (RR = 0.93, 95%
CI = 0.86–1.0, P = 0.045).
SARS‐CoV‐2 infection by smoking status
Forty‐five studies provided data on SARS‐CoV‐2 infection
for people meeting local testing criteria by smoking status
(see Table 2). Meta‐analyses were performed for one ‘good’
and 16 ‘fair’ quality studies (see Figs 3 and 4). Current
smokers were at reduced risk of testing positive for SARS‐
CoV‐2 compared with never smokers (RR = 0.74, 95%
CrI = 0.58–0.93, τ = 0.41, 95% CI = 0.24–0.64). The
FIGURE 2 (a) Weighted mean prevalence of current smoking in included studies with 95% bootstrap confidence intervals (CIs) compared with
national current smoking prevalence (solid red lines), split by country. Shape corresponds to study setting (community, community and hospital, hos-
pital) and shape size corresponds to relative study sample size. (b) Weighted mean prevalence of former smoking in included studies (where this was
reported) with 95% bootstrap CIs compared with national former smoking prevalence (solid red lines), split by country. Shape corresponds to study
setting (community, community and hospital, hospital) and shape size corresponds to relative study sample size. [Colour figure can be viewed at
wileyonlinelibrary.com]
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probability of current smokers being at reduced risk of
infection compared with never smokers (RR ≤ 0.9) was
95%. Former compared with never smokers were at
increased risk of testing positive, but datawere inconclusive
(RR = 1.05, 95% CrI = 0.95–1.17, τ = 0.17, 95%
CI = 0.10–0.26) and favoured there being no important
association. The probability of former smokers being at
increased risk of infection (RR ≥ 1.1) compared with never
smokers was 21%. Results were materially unchanged in
the two sensitivity analyses (see Supporting information,
Fig. S2).
Hospitalization for COVID‐19 by smoking status
Twenty‐nine studies examined hospitalization for
COVID‐19disease stratified by smoking status (see Table 3).
Meta‐analyses were performed for eight ‘fair’ quality
studies (see Figs 5 and 6). Current (RR = 1.06,
CrI = 0.82–1.35, τ = 0.27, 95% CI = 0.08–0.55) and
former (RR = 1.20, CrI = 1.03–1.44, τ = 0.17, 95%
CI = 0.06–0.37) compared with never smokers were at
increased risk of hospitalization with COVID‐19, but data
for current smokers were inconclusive, and favoured there
being no important association. The probability of current
and former smokers being at increased risk of hospitaliza-
tion compared with never smokers was 35 and 89%,
respectively. Results were materially unchanged in two
sensitivity analyses (see Supporting information, Fig. S3).
Disease severity by smoking status
Sixty studies reported disease severity in hospitalized
patients stratified by smoking status (see Table 4). Severe
(as opposed to non‐severe) disease was broadly defined
as requiring intensive treatment unit (ITU) admission, re-
quiring oxygen as a hospital inpatient or in‐hospital death.
Meta‐analyses were performed for eight ‘fair’ quality stud-
ies (see Figs 7 and 8). Current (RR = 1.25, CrI = 0.85–
1.93, τ = 0.34, 95% CI = 0.01–0.86) and former
(RR = 1.52, CrI = 1.13–2.07, τ = 0.29, 95% CI = 0.47–
0.66) compared with never smokers were at increased risk
of greater disease severity; data for current smokers were
inconclusive, but favoured there being a small but impor-
tant association. The probability of current and former
smokers having increased risk of greater disease severity
compared with never smokers was 79 and 98%, respec-
tively. Results were materially unchanged in two sensitivity
analyses (see Supporting information, Fig. S4).
FIGURE 2 Continued.
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FIGURE 3 Forest plot for risk of testing positive for SARS‐CoV‐2 in current versus never smokers. *This was a ‘good’ quality study. [Colour figure
can be viewed at wileyonlinelibrary.com]
FIGURE 4 Forest plot for risk of testing positive for SARS‐CoV‐2 in former versus never smokers. *This was a ‘good’ quality study. [Colour figure
can be viewed at wileyonlinelibrary.com]
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FIGURE 5 Forest plot for risk of hospitalization in current versus never smokers. [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 6 Forest plot for risk of hospitalization in former versus never smokers. [Colour figure can be viewed at wileyonlinelibrary.com]
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FIGURE 7 Forest plot for the risk of severe disease in current versus never smokers. [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 8 Forest plot for the risk of severe disease in former versus never smokers. [Colour figure can be viewed at wileyonlinelibrary.com]
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Mortality by smoking status
Fifty studies reportedmortality fromCOVID‐19 by smoking
status (see Table 5), with nine ‘fair’ quality studies included
in meta‐analyses (see Figs 9 and 10). Current (RR = 1.22,
95% CrI = 0.78–1.94, τ = 0.49, 95% CI = 0.16–0.99) and
former (RR = 1.39, 95% CrI = 1.09–1.87, τ = 0.27, 95%
CI = 0.05–0.58) compared with never smokers were at in-
creased risk of in‐hospital mortality from COVID‐19. Data
for current smokers were inconclusive, but favoured there
being no important association. The probability of current
and former smokers being at greater risk of in‐hospital
mortality compared with never smokers was 70 and
97%, respectively. Results were materially unchanged in
two sensitivity analyses (see Supporting information,
Fig. S5).
DISCUSSION
This living rapid review found uncertainty in the major-
ity of 233 studies arising from the recording of smoking
status. Notwithstanding these uncertainties, compared
with overall adult national prevalence estimates, recorded
current smoking rates in most countries were lower than
expected. In a subset of better of quality studies (n = 17),
current smokers had a reduced risk of testing positive
for SARS‐CoV‐2 but appeared more likely to present for
testing and/or receive a test. Data for current smokers
on the risk of hospitalization, disease severity and
mortality were inconclusive, but favoured there being
no important associations with hospitalization and
mortality and a small but important increase in the risk
of severe disease. Former smokers were at increased risk
of hospitalization, disease severity and mortality com-
pared with never smokers.
Issues complicating interpretation
Interpretation of results from studies conducted during the
first phase of the SARS‐CoV‐2 pandemic is complicated by
several factors (see Fig. 11):
1. Exposure to SARS‐CoV‐2 is heterogeneous, with differ-
ent subgroups at heightened risk of infection at differ-
ent stages of the pandemic. This will likely introduce
bias in studies assessing the rate of infection by
smoking status conducted early on.
2. Current and former smokers may be more likely to
meet local criteria for community testing due to in-
creased prevalence of symptoms consistent with
SARS‐CoV‐2 infection, such as cough, increased spu-
tum production or altered sense of smell or taste
[35]. Evidence from a small number of studies indi-
cates that current smokers may be more likely to pres-
ent for testing, hence increasing the denominator in
comparisons with never smokers and potentially
inflating the rate of negative tests in current smokers.
Infection positivity rates estimated among random
samples will be more informative than currently
available data.We identified one population study con-
ducted in Hungary reporting on seroprevalence and
smoking status [36]; however, the response rate was
fairly low, at 58.8%, and the current smoking rate
was 10 percentage points below national prevalence
estimates, thus questioning the representativeness of
the final sample. Smoking status is being collected in
at least two large representative infection and antibody
surveys in the United Kingdom [37,38].
3. Testing for acute infection requires swabbing of the
mucosal epithelium, which may be disrupted in
current smokers, potentially altering the sensitivity of
assays [39].
4. Diagnostic criteria for SARS‐CoV‐2 infection and
COVID‐19 have changed during the course of the pan-
demic [40]. It was not possible to extract details on the
specific RT–PCR technique or platforms used across
the included studies due to reporting gaps. Different
platforms have varying sensitivity and specificity to de-
tect SARS‐CoV‐2 infection.
5. Most included studies relied on EHRs as the source of
information on smoking status. Research shows large
discrepancies between EHRs and actual behaviour
[41]. Known failings of EHRs include implausible
longitudinal changes, such as former smokers being
recorded as never smokers at subsequent hospital
visits [41]. Misreporting on the part of the patient
(perhaps due to perceived stigmatization) has also
been observed, with biochemical measures showing
higher rates of smoking compared with self‐report in
hospitalized patients in the United States [42]. It is
hence possible that under‐reporting of current and
former smoking status in hospitals occurred across
the included studies.
6. Individuals with severe COVID‐19 symptoms may
have stopped smoking immediately before admission
to hospital and may therefore not have been recorded
as current smokers (i.e. reverse causality).
7. Smokers with COVID‐19 may be less likely to receive a
SARS‐CoV‐2 test or present to hospital due to lack of
access to healthcare, and may be more likely to die in
the community from sudden complications (i.e.
self‐selection bias) and thus not be recorded.
8. If there is a protective effect of nicotine on COVID‐19
disease outcomes, abrupt nicotine withdrawal upon
hospitalization may lead to worse outcomes [12].
9. During periods of heightened demand of limited
healthcare resources, current and former smokers
with extensive comorbidities may have reduced prior-
ity for intensive care admission, thus leading to higher
in‐hospital mortality.
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10. Given the lack of knowledge of the disease progression
and long‐term outcomes of COVID‐19, it is unclear
whether studies conducted thus far in the pandemic
have monitored patients for a sufficient time‐period
to report complete survival outcomes or whether they
are subject to early censoring.
11. Reasons for hospitalization vary by country and time
in the pandemic. For example, early cases may have
been hospitalized for isolation and quarantine reasons
and not due to medical necessity. It is plausible that
this may have skewed early data towards less severe
cases. In addition, the observed association between
former smoking and greater disease severity may be
explained by collider bias [43], where conditioning on
a collider (e.g. testing or hospitalization) by design or
analysis may introduce a spurious association between
current or former smoking (a potential cause of testing
or hospitalization) and SARS‐CoV‐2 infection/adverse
outcomes from COVID‐19 (potentially exacerbated by
smoking) [44].
Limitations
This living rapid evidence review was limited by having a
single reviewer extracting data with a second indepen-
dently verifying the data extracted to minimize errors,
restricting the search to one electronic database and one
pre‐print server and by not including at least three large
population surveys due to their reliance upon
self‐reported suspected or confirmed SARS‐CoV‐2 infection
(which means they do not meet our eligibility criteria)
[35,45,46]. We also did not include a large, UK‐based, rep-
resentative seroprevalence study [47] in our meta‐
analyses, as the odds of testing positive in former smokers
was not reported. However, the odds of infection for cur-
rent smokers (odds ratio = 0.64, 95% CI = 0.58–0.71)
was in concordance with the pooled estimate in our
meta‐analysis. Population surveys—particularly with
linked data on confirmed infection or antibodies—will be
included in future review versions to help mitigate some
of the limitations of healthcare based observational studies.
The comparisons of current and former smoking preva-
lence in the included studies with national prevalence esti-
mates did not adjust observed prevalence for the
demographic profile of those tested/admitted to hospital.
Other reviews focused on this comparison have applied ad-
justments for sex and age, and continue to find lower than
expected prevalence—notwithstanding the issues compli-
cating interpretation described above [17].
Implications for research, policy and practice
Further scientific research is needed to resolve the mixed
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FIGURE 9 Forest plot for the risk of mortality in current versus never smokers. [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 10 Forest plot for the risk of mortality in former versus never smokers. [Colour figure can be viewed at wileyonlinelibrary.com]
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the posited therapeutic effect of nicotine could have im-
portant implications both for smokers and for improved
understanding of how the SARS‐CoV‐2 virus causes dis-
ease in humans. Such trials should focus upon medicinal
nicotine (as smoked tobacco is a dirty delivery mecha-
nism that could mask beneficial effects) and potentially
differentiate between different modes of delivery (i.e. in-
haled versus ingested), as this can affect pharmacokinet-
ics [48] and potential therapeutic effects. A second
research priority would be a large, representative (ran-
domly sampled) population survey with a validated as-
sessment of smoking status which distinguishes
between recent and long‐term ex‐smokers—ideally bio-
chemically verified—and assesses seroprevalence and
links to health records.
In themeantime, public‐facingmessages about the pos-
sible protective effect of smoking or nicotine are premature.
In our view, until there is further research, the quality of
the evidence does not justify the huge risk associated with
a message likely to reachmillions of people that a lethal ac-
tivity, such as smoking, may protect against COVID‐19. It
continues to be appropriate to recommend smoking cessa-
tion and emphasize the role of alternative nicotine prod-
ucts to support smokers to stop as part of public health
efforts during COVID‐19. At the very least, smoking cessa-
tion reduces acute risks from cardiovascular disease and
could reduce demands on the health‐care system [49].
GPs and other health‐care providers can play a crucial
role—brief, high‐quality and free on‐line training is
available at National Centre for Smoking Cessation and
Training.
CONCLUSION
Across 233 studies, recorded smoking prevalence was gen-
erally lower than national prevalence estimates. Current
smokers were at reduced risk of testing positive for SARS‐
CoV‐2 and former smokers were at increased risk of hospi-
talization, disease severity and mortality compared with
never smokers.
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